# Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

> **NCT03361852** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Rituximab
- **BIOLOGICAL:** Neo Vax
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03361852
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2033-12-26
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03361852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03361852, "Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03361852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*